<DOC>
	<DOCNO>NCT00651508</DOCNO>
	<brief_summary>The purpose study determine Objective Response Rate KOS-1584 , single agent patient stage IIIB/IV NSCLC whose disease progress follow initial chemotherapy .</brief_summary>
	<brief_title>Study Evaluate KOS-1584 Patients With Advanced Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologically cytologically proven NSCLC , Stage IIIB Stage IV . Eligible patient must receive one prior chemotherapy regime Stage IIIB/IV NSCLC . Good performance status . Prior treatment epothilone . Known central nervous system ( CNS ) metastasis . Any chemotherapy , radiation therapy immunotherapy investigational agent ( therapeutic diagnostic ) within 3 week prior first study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Patients Advanced Metastatic stage IIIB/IV Non-Small Cell Lung Cancer</keyword>
</DOC>